Phase 3 Colorectal Cancer Trial, Recruiting NCT03659448 Sponsor: Surgimab Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 3 Colorectal Cancer Trial, Recruiting

NCT03659448
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are scheduled for surgery aimed at curing colorectal cancer, including advanced colon cancer (called cT4), rectal cancer that has grown into or through the bowel wall (cT3 or cT4), colorectal cancer that has come back, or colorectal cancer that has spread to the lining of the abdomen.
  • Women who cannot become pregnant — including those who have had their tubes tied, had their uterus or ovaries removed, or have gone through menopause — are eligible. Women who could potentially become pregnant may also be considered, provided they have a negative pregnancy test on the day of the injection and agree to use adequate contraception for 30 days before and 30 days after the injection.

Who may not be able to join:

  • People who currently have, or have been diagnosed with, another cancer in the last 5 years — with exceptions for certain treated skin cancers or a treated early-stage cervical condition.
  • People whose cancer started in the appendix.
  • People whose blood test results show certain liver, kidney, or blood cell levels that fall outside acceptable ranges — the trial site can advise on the specific values.
  • People who have tested positive for HIV, hepatitis B, or hepatitis C, or who have a serious untreated infection.
  • People who have any other health condition that the trial doctor believes could put them at risk or affect the trial's goals (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alex L. Vahrmeijer,, MD, PhD, Leiden University Medical Center, Leiden, The Netherlands

Phone: 8123257657

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Surgimab
Registry
ClinicalTrials.gov
Start date
17 June 2019
Est. completion
1 November 2024

Where this trial is recruiting

🇩🇪 Germany 🇮🇹 Italy 🇳🇱 Netherlands 🇺🇸 United States

Primary endpoints

Surgical resection histopathology.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov